How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials.

Leucht, S, Arbter, D, Engel, R R, Kissling, W, Davis, J M·2009·Molecular Psychiatry
DOI 10.1038/sj.mp.4002136

Cited by (489)

Items 201–300 of 489

  1. Association of End Point Definition and Randomized Clinical Trial Duration in Clinical Trials of Schizophrenia Medications
    Islam Rasem Younis, Mathangi Gopalakrishnan, Mitchell V. Mathis, Mehul Mehta, Ramana S. Uppoor, Hao Zhu, Tiffany R. Farchione · 2020 · JAMA Psychiatry
  2. Symptomatic versus disease‐modifying effects of psychiatric drugs
    S. Nassir Ghaemi · 2022 · Acta Psychiatrica Scandinavica
  3. How should we design future mechanistic and/or efficacy clinical trials?
    Maurizio Fava M. D · 2023 · Neuropsychopharmacology
  4. Patient perspectives in the development and use of long-acting antipsychotics in schizophrenia: focus on olanzapine long-acting injection
    Leslie Citrome · 2009 · Patient Preference and Adherence
  5. Should people with psychosis be supported in choosing cognitive therapy as an alternative to antipsychotic medication: A commentary on current evidence
    Anthony P. Morrison · 2018 · Schizophrenia Research
  6. Time to all-cause treatment discontinuation of olanzapine compared to other antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis
    Karla Soares‐Weiser, Laura Béchard‐Evans, Anthony H. Lawson, John M. Davis, Haya Ascher‐Svanum · 2012 · European Neuropsychopharmacology
  7. Explaining Attitudes and Adherence to Antipsychotic Medication: The Development of a Process Model
    Martin Wiesjahn, Esther Jung, Fabian Lamster, Winfried Rief, Tania M. Lincoln · 2014 · Schizophrenia Research and Treatment
  8. Towards Medication-Enhancement of Cognitive Interventions in Schizophrenia
    Hsun‐Hua Chou, Elizabeth W. Twamley, Neal R. Swerdlow · 2012 · Handbook of experimental pharmacology
  9. EEG Microstate Differences in Medicated vs. Medication-Naïve First-Episode Psychosis Patients
    Amatya Mackintosh, Stefan Borgwardt, Erich Studerus, Anita Riecher‐Rössler, Renate de Bock, Christina Andreou · 2020 · Frontiers in Psychiatry
  10. Psychoeducation, motivational interviewing, cognitive remediation training, and/or social skills training in combination for psychosocial functioning of patients with schizophrenia spectrum disorders: A systematic review and meta-analysis of randomized controlled trials
    Erin Yiqing Lu, Andy S. K. Cheng, Hector W. H. Tsang, Juan Chen, Samuel Leung, Annie Lk Yip, Jingxia Lin, Zoe Violet Lam, Wufang Zhang, Miaomiao Zhao et al. · 2022 · Frontiers in Psychiatry
  11. Analysis of sociability and preference for social novelty in the acute and subchronic phencyclidine rat
    Claire E. McKibben, Gavin P. Reynolds, Trisha A. Jenkins · 2014 · Journal of Psychopharmacology
  12. Applying a Fast-Scan Cyclic Voltammetry to Explore Dopamine Dynamics in Animal Models of Neuropsychiatric Disorders
    Vladimir P. Grinevich, Amir N. Zakirov, Uliana V. Berseneva, Elena Gerasimova, Raul R. Gainetdinov, Evgeny A. Budygin · 2022 · Cells
  13. Sex and pubertal influences on the neurodevelopmental underpinnings of schizophrenia: A case for longitudinal research on adolescents
    Marjolein E.A. Barendse, G.A. Lara, Amanda E. Guyer, Johnna R. Swartz, Sandra L. Taylor, Elizabeth Anne Shirtcliff, Shannon T Lamb, C. Miller, Jason Ng, Guangjun Yu et al. · 2023 · Schizophrenia Research
  14. Antipsychotics and their Side Effects
    David Martin Gardner, Michael D. Teehan, Ross J. Baldessarini · 2010 · Cambridge University Press eBooks
  15. Asenapine
    Herbert Y. Meltzer, Argyris Dritselis, Uma Yasothan, Peter N. Kirkpatrick · 2009 · Nature Reviews Drug Discovery
  16. Using the back door: metacognitive training for psychosis.
    Kumar, Devvarta, Menon, Mahesh, Moritz, Steffen, Woodward, Todd S. · 2015 · Psychosis
  17. The Black Book of Psychotropic Dosing and Monitoring
    Charles DeBattista, Alan F. Schatzberg · 2025 · Psychopharmacology Bulletin
  18. Comparing tolerability profile of quetiapine, risperidone, aripiprazole and ziprasidone in schizophrenia and affective disorders: a meta-analysis
    Hoda Moteshafi, Émmanuel Stip · 2012 · Expert Opinion on Drug Safety
  19. Clinical utility of the risperidone formulations in the management of schizophrenia
    Vishal Madaan · 2011 · Neuropsychiatric Disease and Treatment
  20. Effect of a Telephone Intervention Upon Self-Reported Medication Adherence and Self-Efficacy in Outpatients With Schizophrenia Spectrum Disorders (SSDs)
    Lora Humphrey Beebe, Kathlene Smith, Chad Phillips · 2016 · Issues in Mental Health Nursing
  21. The role of trust and hope in antipsychotic medication reviews between GPs and service users a realist review
    Lisa Marie Grünwald, Claire Duddy, Richard Byng, Nadia E. Crellin, Joanna Moncrieff · 2021 · BMC Psychiatry
  22. Real-world outcomes post-transition to once-every-3-months paliperidone palmitate in patients with schizophrenia within US commercial plans
    Bruno Émond, Antoine C. El Khoury, Charmi A. Patel, Dominic Pilon, Laura Morrison, Maryia Zhdanava, Patrick Lefèbvre, Neeta Tandon, Kruti Joshi · 2018 · Current Medical Research and Opinion
  23. Neuroanatomical Features That Predict Response to Electroconvulsive Therapy Combined With Antipsychotics in Schizophrenia: A Magnetic Resonance Imaging Study Using Radiomics Strategy
    Yibin Xi, Long‐Biao Cui, Jie Gong, Yu‐Fei Fu, Xu‐Sha Wu, Fan Guo, Xuejuan Yang, Chen Li, Xing‐Rui Wang, Ping Li et al. · 2020 · Frontiers in Psychiatry
  24. Australian mental health staff response to antipsychotic medication side effects – the perceptions of consumers
    Paul Morrison, Tom Meehan, Norman Jay Stomski · 2015 · Advances in Mental Health
  25. Unlocking the Therapeutic Potential of Ulotaront as a Trace Amine-Associated Receptor 1 Agonist for Neuropsychiatric Disorders
    Savelii R. Kuvarzin, Ilya Sukhanov, Kirill Onokhin, Захаров Константин Анатольевич, Raul R. Gainetdinov · 2023 · Biomedicines
  26. Lessons to be Learned from Placebo Arms in Psychopharmacology Trials
    Bettina K. Doering, Winfried Rief, Keith J. Petrie · 2014 · Handbook of experimental pharmacology
  27. Quetiapine immediate release v. placebo for schizophrenia: systematic review, meta-analysis and reappraisal
    Paul Hutton, Peter James Taylor, Lee D. Mulligan, Sarah Tully, Joanna Moncrieff · 2015 · The British Journal of Psychiatry
  28. Opinion Piece: The case for establishing a minimal medication alternative for psychosis and schizophrenia
    Ruth E Cooper, J Mason, Tim Calton, John M. Richardson, Joanna Moncrieff · 2021 · Psychosis
  29. Hallucinations in acutely admitted patients with psychosis, and effectiveness of risperidone, olanzapine, quetiapine, and ziprasidone: a pragmatic, randomized study
    Erik Johnsen, Igne Sinkeviciute, Else‐Marie Løberg, Rune A. Kroken, Kenneth Hugdahl, Hugo Arild Jørgensen · 2013 · BMC Psychiatry
  30. Effectiveness of acceptance and commitment therapy for inpatients with psychosis: Implementation feasibility and acceptability from a pilot randomized controlled trial
    Brandon A. Gaudiano, Stacy Ellenberg, Jennifer E. Johnson, Kim T. Mueser, Ivan W. Miller · 2023 · Schizophrenia Research
  31. The need for E xperience F ocused C ounselling ( EFC ) with voice hearers in training and practice: a review of the literature
    Joachim Schnackenberg, Colin Robert Martin · 2013 · Journal of Psychiatric and Mental Health Nursing
  32. Burning issues in the meta-analysis of pharmaceutical trials for depression
    Konstantinos Ν. Fountoulakis, Myrto T. Samara, Melina Siamouli · 2013 · Journal of Psychopharmacology
  33. How antipsychotics impact the different dimensions of Schizophrenia: A test of competing hypotheses
    Tiago Reis Marques, Stephen Z. Levine, Avi Reichenberg, René S. Kahn, Eske M. Derks, Wolfgang Fleischhacker, Jonathan Rabinowitz, Shitij Kapur · 2014 · European Neuropsychopharmacology
  34. Symptômes négatifs de la schizophrénie : une revue des instruments d’évaluation
    Cyril Mach, Sonia Dollfus · 2016 · L Encéphale
  35. Symptoms, functioning and coping strategies in individuals with schizophrenia spectrum disorders who do not take antipsychotic medication: a comparative interview study
    Esther Jung, Martin Wiesjahn, Hanna Wendt, Thomas A. Bock, Winfried Rief, Tania M. Lincoln · 2016 · Psychological Medicine
  36. Lack of association between dopaminergic antagonism and negative symptoms in schizophrenia: a positron emission tomography dopamine D2/3 receptor occupancy study
    Gagan Fervaha, Fernando Caravaggio, David C. Mamo, Benoit H. Mulsant, Bruce G. Pollock, Shinichiro Nakajima, Philip Gerretsen, Tarek K. Rajji, Wanna Mar, Yusuke Iwata et al. · 2016 · Psychopharmacology
  37. The mediating role of depression in pathways linking positive and negative symptoms in schizophrenia. A longitudinal analysis using latent variable structural equation modelling
    Giuseppe Carrà, Cristina Crocamo, Francesco Bartoli, Matthias C. Angermeyer, Traolach Sean Brugha, Mondher Toumi, Paul Bebbington · 2019 · Psychological Medicine
  38. Drug treatment developments in schizophrenia and bipolar mania: latest evidence and clinical usefulness
    Erik Johnsen, Rune A. Kroken · 2012 · Therapeutic Advances in Chronic Disease
  39. Efficacy of Remotely Delivered Evidence-Based Psychosocial Treatments for Schizophrenia-Spectrum Disorders: A Series of Systematic Reviews and Meta-Analyses
    Michael W. Best, Sylvia Romanowska, Ying Zhou, Linbo Wang, Talia Leibovitz, Karin A. Onno, Shreya Jagtap, Christopher R. Bowie · 2023 · Schizophrenia Bulletin
  40. Experiences of Family Carers for Persons Using Antipsychotic Medication
    Paul Morrison, Norman Jay Stomski · 2017 · Australian and New Zealand Journal of Family Therapy
  41. Pharmacological treatment of schizophrenia
    Ary Gadelha, Cristiano de Souza Noto, Jair de Jesus Mari · 2012 · International Review of Psychiatry
  42. International Consensus Study of Antipsychotic Dosing
    David Martin Gardner, Andrea Lynn Murphy, Heather O’Donnell, Franca Centorrino, Ross J. Baldessarini · 2014 · FOCUS The Journal of Lifelong Learning in Psychiatry
  43. Descriptions and Correlates of Medication Adherence, Attitudes, and Self-Efficacy in Outpatients With Schizophrenia Spectrum Disorders (SSDs)
    Lora Humphrey Beebe, Kathy Smith, Chad Phillips · 2016 · Archives of Psychiatric Nursing
  44. Therapeutic Drug Monitoring for individualised risk reduction in psychopharmacotherapy
    Gregor A. Schütze, Markus Schwarz · 2016 · TrAC Trends in Analytical Chemistry
  45. Recent Discussions on Dopamine Supersensitivity Psychosis: Eight Points to Consider When Diagnosing Treatment-Resistant Schizophrenia
    Nobuhisa Kanahara, Hiroshi Kimura, Yasunori Oda, Fumiaki Ito, Masaomi Iyo · 2021 · Current Neuropharmacology
  46. Cost-effectiveness of long-acting injectable risperidone versus flupentixol decanoate in the treatment of schizophrenia: a Markov model parameterized using administrative data
    Simon Frey, Roland Linder, Georg Juckel, Tom Stargardt · 2013 · The European Journal of Health Economics
  47. Quetiapine versus aripiprazole in children and adolescents with psychosis - protocol for the randomised, blinded clinical Tolerability and Efficacy of Antipsychotics (TEA) trial
    Anne Katrine Pagsberg, Pia Jeppesen, Dea Gowers Klauber, Karsten Gjessing Jensen, Ditte Rudå, Marie Stentebjerg-Olesen, Peter Jantzen, Simone Rasmussen, Eva Ann-Sofie Saldeen, Maj-Britt Glenn Lauritsen et al. · 2014 · BMC Psychiatry
  48. Increasing placebo response in antipsychotic trials: a clinical perspective
    Markus Dold, Siegfried F. Kasper · 2015 · Evidence-Based Mental Health
  49. Symptom-related attributional biases in schizophrenia and bipolar disorder
    Nicole Sanford, Todd Stephen Woodward · 2017 · Cognitive Neuropsychiatry
  50. Schizotypy and auditory mismatch negativity in a non-clinical sample of young adults
    Samantha J. Broyd, Patricia Therese Michie, Jason M. Bruggemann, Hendrika H. van Hell, Lisa‐Marie Greenwood, Rodney J. Croft, Juanita Todd, Rhoshel Lenroot, Nadia Solowij · 2016 · Psychiatry Research Neuroimaging
  51. Update of the World Health Organization’s Mental Health Gap Action Programme Guideline for Psychoses (Including Schizophrenia)
    Carolin Lorenz, Irene Bighelli, Fahmy Hanna, Aemal Akhtar, Stefan Leucht · 2024 · Schizophrenia Bulletin
  52. Unlocking the secrets of trace amine-associated receptor 1 agonists: new horizon in neuropsychiatric treatment
    Britto Shajan, Tarun Joseph Bastiampillai, Shane D. Hellyer, Pramod C. Nair · 2024 · Frontiers in Psychiatry
  53. Assessing Cognitive Therapy Instead Of Neuroleptics: Rationale, study design and sample characteristics of the ACTION trial
    Anthony P. Morrison, Melissa Wardle, Paul Hutton, Linda Mary Davies, Graham Dunn, Alison Brabban, Rory Edward Byrne, Laura Drage, Helen M. Spencer, Douglas Turkington · 2013 · Psychosis
  54. Treatment-refractory schizophrenia: what is it and what has been done about it?
    Leslie Citrome · 2011 · Neuropsychiatry
  55. Bad things happen and can drive you crazy: The causal beliefs of 701 people taking antipsychotics
    John Read · 2020 · Psychiatry Research
  56. Personality characteristics of psychotic patients as possible motivating factors for participating in group psychotherapy.
    Branka Restek-Petrović, Anamarija Bogović, Majda Grah, Igor Filipčić, Ena Ivezić · 2015 · PubMed
  57. Medications for First-Episode Psychosis: Making a Good Start
    Lisa B. Dixon, T. Scott Stroup · 2015 · American Journal of Psychiatry
  58. Implementing gradual, hyperbolic tapering of long-acting injectable antipsychotics by prolonging the inter-dose interval: an in silico modelling study
    O’Neill, James R., Taylor, David M., Horowitz, Mark A. · 2023 · Therapeutic Advances in Psychopharmacology
  59. Improving depressive symptoms in patients with schizophrenia using bilateral bipolar-nonbalanced prefrontal tDCS: Results from a double-blind sham-controlled trial
    Jacopo Lisoni, Gabriele Nibbio, Giulia Baldacci, Andrea Zucchetti, Andrea Cicale, Daniela Zardini, Paola Miotto, Giacomo Deste, Stefano Barlati, Antonio Vita · 2024 · Journal of Affective Disorders
  60. Understanding the paranoid psychosis of James: Use of the repertory grid technique for case conceptualization
    Helena García‐Mieres, Susana Ochoa, Marta Salla, Raquel López‐Carrilero, Guillem Feixas · 2016 · World Journal of Psychiatry
  61. Non-pharmacological treatments for schizophrenia in Southeast Europe: An expert survey
    Lidija Injac Stevović, Selman Repišti, Tamara Radojičić, Norman Sartorius, Sonila Tomori, Alma Džubur Kulenović, Ana Popova, Martina Rojnić Kuzman, Ilias I Vlachos, Shukrije Statovci et al. · 2021 · International Journal of Social Psychiatry
  62. Exploring fear of death and psychosis proneness: positive schizotypy as a function of death anxiety and maladaptive coping
    Dane Easden, Caroline Gurvich, Ryan A. Kaplan, Susan Lee Rossell · 2022 · Clinical Psychologist
  63. The role of pharmacists in supporting service users to optimise antipsychotic medication
    Jo Howe, Laura Lindsey · 2023 · International Journal of Clinical Pharmacy
  64. Recovery from psychosis: physical health, antipsychotic medication and the daily dilemmas for mental health nurses
    Daniel Thomas Bressington, John White · 2015 · Journal of Psychiatric and Mental Health Nursing
  65. Cost-effectiveness of asenapine in the treatment of schizophrenia in Canada
    Jean Lachaîne, C. Beauchemin, K. Mathurin, Dominique Gilbert, Maud Beillat · 2014 · Journal of Medical Economics
  66. Effectiveness of amisulpride in Chinese patients with predominantly negative symptoms of schizophrenia: a subanalysis of the ESCAPE study
    Ying Liang, Xin Yu · 2017 · Neuropsychiatric Disease and Treatment
  67. Haloperidol discontinuation for people with schizophrenia
    Adib Essali, Khaled Turkmani, Shaimaa Aboudamaah, Alaa AbouDamaah, Mohammad Reyad Dia'a Aldeen, Mohamad Essam Marwa, Nawar Almounayer · 2019 · Cochrane Database of Systematic Reviews
  68. The Psychosis Recent Onset GRoningen Survey (PROGR-S): Defining Dimensions and Improving Outcomes in Early Psychosis
    Edith Jantine Liemburg, Stynke Castelein, Frank van Es, Anne Neeltje Scholte-Stalenhoef, G. van de Willige, Henderikus G. O. M. Smid, Ellen Visser, Henderikus Knegtering, Richard Bruggeman · 2014 · PLoS ONE
  69. Replication of SULT4A1-1 as a Pharmacogenetic Marker of Olanzapine Response and Evidence of Lower Weight Gain in the High Response Group
    Timothy L. Ramsey, Qian Liu, Mark D. Brennan · 2014 · Pharmacogenomics
  70. Editorial: Non-pharmacological Interventions for Schizophrenia: How Much Can Be Achieved and How?
    Christina Andreou, Steffen Moritz · 2016 · Frontiers in Psychology
  71. Promising Evidence of Antipsychotic Efficacy without Dopamine D2-Receptor Binding
    DONALD C. GOFF · 2020 · New England Journal of Medicine
  72. Guidelines for Discontinuation of Antipsychotics in Patients Who Recover From First-Episode Schizophrenia Spectrum Disorders: Derived From the Aggregated Opinions of Asian Network of Early Psychosis Experts and Literature Review
    Asian Network of Early Psychosis Writing Group, Christy Lai Ming Hui, Eric Yu Hai Chen, Swapna Verma, Hiromi Tagata, Masafumi Mizuno, Chen‐Chung Liu, Hiroyoshi Takeuchi, Sung‐Wan Kim, Young‐Chul Chung · 2022 · The International Journal of Neuropsychopharmacology
  73. Sertindole for the treatment of schizophrenia
    Jean‐Michel Azorin, Arthur Kaladjian, Éric Fakra, M. Adida · 2010 · Expert Opinion on Pharmacotherapy
  74. Sertindole: dilemmas for its use in clinical practice
    Chi‐Un Pae · 2013 · Expert Opinion on Drug Safety
  75. Is Rational Antipsychotic Polytherapy Feasible? A Selective Review
    Rune A. Kroken, Erik Johnsen · 2012 · Current Psychiatry Reports
  76. Neuropsychopharmacology of auditory hallucinations: insights from pharmacological functional MRI and perspectives for future research
    E. Johnsen, K. Hugdahl, P. Fusar-Poli, R. Kroken, K. Kompus · 2013 · Expert Review of Neurotherapeutics
  77. Switching strategies for antipsychotic monotherapy in schizophrenia: a multi-center cohort study of aripiprazole
    Yoshiaki Obayashi, Satoshi Mitsui, Shinji Sakamoto, Nozomu Minao, Bunta Yoshimura, Toshiki Kono, Yuji Yada, Yuko Okahisa, Soshi Takao, Yoshiki Kishi et al. · 2019 · Psychopharmacology
  78. Service-user efforts to maintain their wellbeing during and after successful withdrawal from antipsychotic medication
    Miriam Larsen-Barr, Fred W. Seymour · 2021 · Therapeutic Advances in Psychopharmacology
  79. Influence of Aripiprazole, Risperidone, and Amisulpride on Sensory and Sensorimotor Gating in Healthy ‘Low and High Gating’ Humans and Relation to Psychometry
    Philipp Csomor, Katrin H. Preller, Mark A. Geyer, Erich Studerus, Theodor Huber, Franz X. Vollenweider · 2014 · Neuropsychopharmacology
  80. Opportunities in precision psychiatry using PET neuroimaging in psychosis
    Jennifer Marie Coughlin, Andrew G. Horti, Martin G. Pomper · 2019 · Neurobiology of Disease
  81. Antidepressive Effectiveness of Amisulpride, Aripiprazole, and Olanzapine in Patients With Schizophrenia Spectrum Disorders
    Eirik Kjelby, Rolf Gjestad, Farivar Fathian, Igne Sinkeviciute, Renata Alisauskiene, Liss Gøril Anda, Else‐Marie Løberg, Solveig Klæbo Reitan, Inge Joa, Tor Ketil Larsen et al. · 2023 · Journal of Clinical Psychopharmacology
  82. Cognitive behavioural therapy for psychosis: rationale and protocol for a systematic review and meta-analysis
    Paul Hutton, Lisa Wood, Peter James Taylor, Kerry Irving, Anthony P. Morrison · 2013 · Psychosis
  83. Das letzte Mittel? Ein Überblick über die politische Diskussion und den Forschungsstand zum Einsatz medikamentöser Zwangsbehandlung in der Psychiatrie
    Tania M. Lincoln, Kolja Heumann, Maria Teichert · 2013 · Verhaltenstherapie
  84. Clozapine-induced myocarditis during co-administration of valproate: A case report
    Piotr Pawel Jaholkowski, Julita Niewiadomska, Jacek Wciórka, Mirosław Kowalski, Piotr Świtaj · 2019 · Psychiatria Polska
  85. Characterization of specific and distinct patient types in clinical trials of acute schizophrenia using an uncorrelated PANSS score matrix transform (UPSM)
    Seth C. Hopkins, Ajay Ogirala, Antony D Loebel, Kenneth S. Koblan · 2020 · Psychiatry Research
  86. Aberrant memory and delusional ideation: A pernicious partnership?
    William N. Koller, Tyrone D. Cannon · 2022 · Clinical Psychology Review
  87. Amisulpride for very late-onset schizophrenia-like psychosis: the ATLAS three-arm RCT
    Robert J. Howard, Elizabeth Cort, Rosie Bradley, Emma Harper, Linda J. Kelly, Peter Bentham, Craig William Ritchie, Suzanne Reeves, Waleed Fawzi, Gill Livingston et al. · 2018 · Health Technology Assessment
  88. Re-starting the conversation: improving shared decision making in antipsychotic prescribing
    Lisa Marie Grünwald, Jemima Thompson · 2021 · Psychosis
  89. Experimental drugs for bipolar psychosis
    Michele Fornaro, Antônio Egídio Nardi, Domenico De Berardis, Mauro Giovanni Carta · 2016 · Expert Opinion on Investigational Drugs
  90. Drug-induced Extrapyramidal Symptoms Scale (DIEPSS) Serbian Language version: Inter-rater and Test-retest Reliability
    Amir Peljto, Ljubica Zamurovic, Milica Pejovic Milovancevic, Branko Aleksić, Dušica Lečić Toševski, Toshiya Inada · 2017 · Scientific Reports
  91. Antipsychotics decrease response confidence
    Steffen Moritz, Katharina Kolbeck, Christina Andreou · 2016 · Journal of Psychopharmacology
  92. How close is evidence to truth in evidence-based treatment of mental disorders?
    Hans‐Jürgen Möller · 2011 · European Archives of Psychiatry and Clinical Neuroscience
  93. Feasibility, acceptability and evaluation of meditation to augment yoga practice among persons diagnosed with schizophrenia
    Triptish Bhatia A, Nupur Kumari, Ashok Yadav, Ram Pratap Beniwal, Gyandeepak Shah, Wood Joel, Jacquelynn R. Jones, Satish Iyenger, Vishwajit Laxmikant Nimgaonkar, Smita Neelkanth Deshpande · 2022 · Acta Neuropsychiatrica
  94. The Field of Schizophrenia: Strengths, Weaknesses, Opportunities, and Threats
    John Michael Kane, Barbara A. Cornblatt, Christoph Ulrich Correll, Terry E. Goldberg, Todd Lencz, Anil K. Malhotra, Delbert G. Robinson, Philip R. Szeszko · 2011 · Schizophrenia Bulletin
  95. Prolactin Level in Patients with First Episode Schizophrenia Treated for One Year with Atypical Antipsychotics
    Valentin Petre Matei · 2018 · Acta Endocrinologica (Bucharest)
  96. Perspective on medication decisions following remission from first-episode psychosis
    Christy Lai Ming Hui, Bertha Sze Ting Lam, Edwin Ho Ming Lee, Sherry Kit Wa Chan, Wing Chung Chang, Yi Nam Suen, Eric Yu Hai Chen · 2020 · Schizophrenia Research
  97. One-year Outcome of First vs. Later Episode Schizophrenia: A Real-world Naturalistic Study
    Konstantinos Ν. Fountoulakis, Panagiotis Panagiotidis, Theofilidis Antonis, Ioannis Nimatoudis · 2020 · Clinical Psychopharmacology and Neuroscience
  98. How important are informed consent, informed choice, and patient-doctor relationships, when prescribing antipsychotic medication?
    John Read · 2022 · Journal of Mental Health
  99. STON2 variations are involved in synaptic dysfunction and schizophrenia-like behaviors by regulating Syt1 trafficking
    Yuanlin Ma, Kai Gao, Xiaoxuan Sun, Jinxin Wang, Yang Yang, Jianying Wu, Anping Chai, Yao Li, Nan Liu, Hao Yu et al. · 2024 · 中国科学通报：英文版
  100. Cognitive‐behavioural therapy for schizophrenia: A critical commentary on the Newton‐Howes and Wood meta‐analysis
    Paul Hutton · 2013 · Psychology and Psychotherapy Theory Research and Practice